

# BYQLOVI- clobetasol propionate for suspension

## Harrow Eye, LLC

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BYQLOVI<sup>®</sup> safely and effectively. See full prescribing information for BYQLOVI.

**BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use**  
**Initial U.S. Approval: 1985**

### INDICATIONS AND USAGE

BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. ( 1)

### DOSAGE AND ADMINISTRATION

- Instill one drop of BYQLOVI into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. ( 2.1)
- Wash hands well before each use. ( 2.2)

### DOSAGE FORMS AND STRENGTHS

Ophthalmic suspension containing clobetasol propionate 0.05%. ( 3)

### CONTRAINDICATIONS

BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. ( 4)

### WARNINGS AND PRECAUTIONS

- **Intraocular Pressure (IOP) Increase:** Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. ( 5.1)
- **Cataracts:** Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. ( 5.2)
- **Delayed Healing:** The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. ( 5.3)
- **Corneal and Scleral Melting:** In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. ( 5.4)
- **Bacterial Infections:** Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. ( 5.5)
- **Viral Infections:** Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). ( 5.6)
- **Fungal Infections:** Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. ( 5.7)

### ADVERSE REACTIONS

Ocular adverse reactions occurring in  $\geq 1\%$  of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure ( 6.1).

**To report SUSPECTED ADVERSE REACTIONS, contact Harrow at 1-833-4HARROW(427769) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 9/2025**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

- 2.1 Recommended Dosage
- 2.2 Administration Instructions

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Intraocular Pressure (IOP) Increase
- 5.2 Cataracts
- 5.3 Delayed Healing
- 5.4 Corneal and Scleral Melting
- 5.5 Bacterial Infections
- 5.6 Viral Infections
- 5.7 Fungal Infections
- 5.8 Risk of Contamination
- 5.9 Contact Lens Wear

### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience

### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Storage and Handling

### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

BYQLOVI is indicated for the treatment of post-operative inflammation and pain following

ocular surgery.

## **2 DOSAGE AND ADMINISTRATION**

### **2.1 Recommended Dosage**

Instill one drop of BYQLOVI into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.

### **2.2 Administration Instructions**

Wash hands well before each use.

If using other eye drops in addition to BYQLOVI, wait at least 5 minutes between instillation of BYQLOVI and other eye drops.

## **3 DOSAGE FORMS AND STRENGTHS**

Ophthalmic suspension containing clobetasol propionate 0.05% (0.5 mg/mL).

## **4 CONTRAINDICATIONS**

BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Intraocular Pressure (IOP) Increase**

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If BYQLOVI is used for 10 days or longer, IOP should be monitored.

### **5.2 Cataracts**

Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.

### **5.3 Delayed Healing**

The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.

### **5.4 Corneal and Scleral Melting**

In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.

## **5.5 Bacterial Infections**

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

## **5.6 Viral Infections**

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

## **5.7 Fungal Infections**

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal culture should be taken when appropriate.

## **5.8 Risk of Contamination**

Do not allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.

## **5.9 Contact Lens Wear**

BYQLOVI should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BYQLOVI. The preservative in BYQLOVI may be absorbed by soft contact lenses. Lenses may be reinserted after 15 minutes following administration of BYQLOVI.

## **6 ADVERSE REACTIONS**

The following serious reactions are found elsewhere in the labeling:

- Intraocular Pressure (IOP) Increase [see *Warnings and Precautions ( 5.1)*]
- Posterior Subcapsular Cataract Formation [see *Warnings and Precautions ( 5.2)*]
- Delayed Healing [see *Warnings and Precautions ( 5.3)*]
- Corneal and Scleral Melting [see *Warnings and Precautions ( 5.4)*]
- Bacterial Infections [see *Warnings and Precautions ( 5.5)*]
- Viral Infections [see *Warnings and Precautions ( 5.6)*]
- Fungal Infections [see *Warnings and Precautions ( 5.7)*]

### **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Ocular adverse reactions occurring in  $\geq 1\%$  of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber

inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

There are no adequate and well-controlled clinical studies of BYQLOVI administration in pregnant women to inform drug-associated risks. Plasma concentrations of clobetasol propionate were minimal following topical ophthalmic administration of BYQLOVI [see *Clinical Pharmacology* ( 12.3)] . However, corticosteroids, including clobetasol propionate have been shown to be teratogenic and fetotoxic in laboratory animals when administered systemically at relatively low dosage levels (see *Data*) .

BYQLOVI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

#### Data

##### *Animal Data*

In embryofetal development studies in mice, clobetasol propionate was fetotoxic at the highest subcutaneous dose tested (1 mg/kg) and teratogenic at all subcutaneous dose levels tested down to 0.03 mg/kg. Abnormalities observed included cleft palate and skeletal abnormalities. These doses are approximately 98 times and 3 times, respectively, the recommended human ophthalmic dose of BYQLOVI, estimated based on body surface area and assuming 100% systemic absorption.

In embryofetal development studies in rabbits, clobetasol propionate was teratogenic at subcutaneous doses of 3 and 10 µg/kg. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. These doses are approximately 1.2 times and 3.9 times, respectively, the recommended human ophthalmic dose of BYQLOVI, estimated based on body surface area and assuming 100% systemic absorption.

### **8.2 Lactation**

#### Risk Summary

There is no information regarding the presence of clobetasol propionate in human milk, the effects on the breastfed infant, or the effects on milk production.

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. However, systemic levels of clobetasol propionate following topical ocular administration are minimal [see *Clinical Pharmacology* ( 12.3)], and it is not known whether measurable levels of clobetasol propionate would be present in maternal milk following topical ocular administration.

The developmental and health benefits of breastfeeding should be considered along with

the mother's clinical need for BYQLOVI, and any potential adverse effects on the breastfed infant from BYQLOVI.

## 8.4 Pediatric Use

The safety and effectiveness of BYQLOVI in pediatric patients have not been established.


## 8.5 Geriatric Use

No overall differences in safety and effectiveness of BYQLOVI have been observed between patients 65 years of age and older and younger adult patients.

## 11 DESCRIPTION

BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% contains the active compound clobetasol propionate, a synthetic corticosteroid, that has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Chemically, clobetasol propionate is 21-chloro-9-fluoro-11 $\beta$ ,17-dihydroxy-16 $\beta$ -methylpregna- 1,4-diene-3,20-dione 17-propionate and it has the following structural formula:



Clobetasol propionate has the empirical formula C<sub>25</sub>H<sub>32</sub>ClFO<sub>5</sub> and a molecular weight of 467. BYQLOVI contains a sterile, anti-inflammatory corticosteroid for topical ophthalmic use.

Each mL of BYQLOVI contains:

ACTIVE: clobetasol propionate 0.5 mg (0.05%)

INACTIVES: sodium chloride, hydrogenated soybean lecithin, citric acid, glycerin, poloxamer 407, polyvinyl alcohol, boric acid, edetate disodium dihydrate, methylcellulose, trisodium citrate, and water for injection

PRESERVATIVE: benzalkonium chloride 0.0036%.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory

activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

## **12.2 Pharmacodynamics**

In patients treated with BYQLOVI twice daily for 21 days, the mean (SD) changes from baseline in cortisol concentrations, -18.1 (126.2) nmol/L and +5.1 (129.8) nmol/L for the BYQLOVI and matching vehicle arms, respectively, were not statistically significant, considering the variability observed in the cortisol concentrations.

## **12.3 Pharmacokinetics**

After the first and second (12 hours apart) ocular instillations of BYQLOVI in healthy adults (n=12), peak plasma clobetasol propionate concentrations (C<sub>max</sub>) were below the lower limit of quantitation (LLOQ, 0.04 ng/mL) in 13 out of 22 PK profiles and ranged from 0.040 to 0.182 ng/mL in the other 9 profiles. Time to peak concentration (T<sub>max</sub>) was observed between 0.5 - 1 hour post-dose. Clobetasol propionate concentrations declined to lower than LLOQ after 4 to 5 hours post-dose.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Carcinogenesis

Long-term animal studies have not been performed with BYQLOVI to evaluate the carcinogenic potential of clobetasol propionate.

#### Mutagenesis

Clobetasol propionate was not mutagenic in 3 different test systems: the Ames test, the *Saccharomyces cerevisiae* gene conversion assay, and the *E. coli* B WP2 fluctuation test.

#### Impairment of Fertility

Fertility studies in the rat following subcutaneous administration at dosage levels up to 50 µg/kg/day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. This dose is approximately 10 times the recommended human ophthalmic dose of BYQLOVI (0.83 µg/kg/day), estimated based on body surface area and assuming 100% systemic absorption. Note that systemic levels of clobetasol propionate following topical ocular administration are minimal [*see Clinical Pharmacology ( 12.3)*].


## **14 CLINICAL STUDIES**

Clinical efficacy was evaluated in 2 multi-center, randomized, double-masked, vehicle-controlled trials in which patients had ≥10 cells in the anterior chamber after cataract surgery were assigned to BYQLOVI 0.05% (N=366) or vehicle (N=382) (NCT04739709


(Study 1) and NCT04810962 (Study 2)). One drop of BYQLOVI 0.05% or vehicle was self-administered twice a day for 14 days, beginning on the day after surgery. Complete resolution of inflammation (an anterior chamber cell count of 0 maintained through Day 15 without rescue medication) and complete resolution of pain (a patient-reported pain grade of 0 maintained through Day 15 without rescue medication) were assessed at post-operative day (POD) 4, 8, and 15.

The co-primary efficacy endpoints were the proportion of subjects with Anterior Chamber Cell (ACC) count = 0 (ACC grade = 0) at POD8 maintained through POD15, and the proportion of subjects with Ocular Pain Grade = 0 at POD4 maintained through POD15. In the intent-to-treat analysis, both co-primary efficacy endpoints were statistically significantly better in BYQLOVI 0.05%-treated patients compared to vehicle-treated patients ( $p < 0.01$ ). The clinical trial efficacy results from both studies are provided below.

**Figure 1: Percent of Patients with Anterior Chamber Cell Count = 0 at Post-Operative Days 8 and 15**



**Figure 2: Percent of Patients with Complete Resolution of Pain at Post-Operative Days 4, 8, and 15**



## 16 HOW SUPPLIED/STORAGE AND HANDLING

### 16.1 How Supplied

BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% (0.5 mg/mL) is a sterile ophthalmic suspension. It is supplied in a multi-dose white low-density polyethylene plastic 5 mL eye-dropper bottle with a low-density polyethylene white tip and a high-density polyethylene pink cap with a tamper-proof ring at the bottom of the cap.

3.5 mL in a 5 mL bottle (NDC 82667-021-05)

## **16.2 Storage and Handling**

- Do not use if tamper-evident ring seal is broken.
- Keep the bottle tightly closed with the pink cap when not in use.

Store upright at 15°C to 25°C (59°F to 77°F). Do not freeze. After opening, BYQLOVI can be used until the expiration date on the bottle.

## **17 PATIENT COUNSELING INFORMATION**

### Administration with Other Eye Drops

Advise patients to wait at least 5 minutes between instillation of BYQLOVI and other eye drops if using other eye drops in addition to BYQLOVI.

### Risk of Contamination

Advise patients to wash their hands well before each use. Advise patients not to allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.

### When to Seek Physician Advice

Advise patients to consult a physician if pain develops; or if redness, itching, or inflammation becomes aggravated.

### Contact Lens Wear

Advise patients that the preservative in BYQLOVI may be absorbed by soft contact lenses.

Contact lenses should be removed prior to instillation of BYQLOVI and may be reinserted after 15 minutes following administration.

Distributed by:

Harrow Eye, LLC™

Nashville, TN 37215, USA

960204000074

Rev. 09/2025

## **Principal Display Panel - 3.5 mL Carton Label**

NDC 82667-021-05

**Rx only**

**BYQLOVI**

(clobetasol propionate  
ophthalmic suspension)

0.05%

FOR TOPICAL APPLICATION  
IN THE EYE

3.5mL **Sterile**

LOT NO:  
EXP:

NDC 82667-021-05

**Rx only**



**BYQLOVI**

(clobetasol propionate  
ophthalmic suspension)  
0.05%

FOR TOPICAL APPLICATION  
IN THE EYE

3.5mL **Sterile**



↑ **Store upright** ↑

Each mL contains:

**Active:** clobetasol propionate  
0.5 mg/mL (0.05%)

**Inactives:**  
lecithin, citric acid, glycerin,  
poloxamer 407,  
polyvinylalcohol, boric acid,  
edetate disodium dihydrate,  
methylcellulose, sodium  
citrate, water for injection

**Preservatives:**  
benzalkonium chloride

Distributed by:  
Harrow Eye, LLC™  
Nashville, TN 37215, USA



**FOR TOPICAL APPLICATION  
IN THE EYE**

**Dosage:** See Prescribing  
Information

**Storage:** Store upright at  
15°C to 25°C (59°F to 77°F)

**DO NOT FREEZE**

**DO NOT USE IF  
TAMPER-EVIDENT  
OVERCAP IS NOT INTACT**

↑ **Store upright** ↑

NDC 82667-021-05 **Rx only**

**BYQLOVI**

(clobetasol propionate  
ophthalmic suspension)  
0.05%

3.5mL **Sterile**

960204000075

# Principal Display Panel - 3.5 mL Bottle Label

Rx only NDC: 82667-021-05

## BYQLOVI

(clobetasol propionate  
ophthalmic suspension) 0.05%

**FOR TOPICAL APPLICATION  
IN THE EYE**

**Sterile 3.5 mL**

<b>Each mL Contains:</b> <b>Active:</b> clobetasol propionate 0.5 mg/mL (0.05%) <b>Distributed by:</b> Harrow Eye, LLC™ Nashville, TN 37215, USA  <b>HARROW®</b>	<b>Rx only</b> NDC: 82667-021-05 <b>BYQLOVI</b> (clobetasol propionate ophthalmic suspension) 0.05% <b>FOR TOPICAL APPLICATION IN THE EYE</b> <b>Sterile</b> <b>3.5 mL</b>	<b>Dosage:</b> See Prescribing Information <b>Storage:</b> Store upright at 15°C to 25°C (59°F to 77°F) DO NOT FREEZE <b>DO NOT USE IF TAMPER-EVIDENT OVERCAP IS NOT INTACT</b>	 82667 02105 6 LOT: EXP:	960204000073
--	--	--	--	--------------

## BYQLOVI

clobetasol propionate for suspension

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:82667-021
<b>Route of Administration</b>	OPHTHALMIC		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>CLOBETASOL PROPIONATE</b> (UNII: 779619577M) (CLOBETASOL - UNII:ADN79D536H)	CLOBETASOL PROPIONATE	0.5 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	
<b>HYDROGENATED SOYBEAN LECITHIN</b> (UNII: H1109Z9J4N)	
<b>CITRIC ACID MONOHYDRATE</b> (UNII: 2968PHW8QP)	
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	
<b>POLOXAMER 407</b> (UNII: TUF2IVW3M2)	
<b>POLYVINYL ALCOHOL, UNSPECIFIED</b> (UNII: 532B59J990)	
<b>BORIC ACID</b> (UNII: R57ZHV85D4)	
<b>EDETATE DISODIUM</b> (UNII: 7FLD91C86K)	
<b>METHYLCELLULOSE, UNSPECIFIED</b> (UNII: Z944H5SN0H)	

**ANHYDROUS TRISODIUM CITRATE** (UNII: RS7A450LGA)

**WATER** (UNII: 059QF0KO0R)

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:82667-021-05	1 in 1 CARTON	01/25/2026	
1		3.5 mL in 1 BOTTLE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
2	NDC:82667-021-00	1 in 1 CARTON	01/25/2026	
2		3.5 mL in 1 BOTTLE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA218158	03/04/2024	

**Labeler** - Harrow Eye, LLC (118526951)

Revised: 1/2026

Harrow Eye, LLC